Aligos Therapeutics (ALGS) Revenue (2021 - 2026)

Aligos Therapeutics (ALGS) has reported Revenue for 6 consecutive years, with $2.8 million the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 809.97% year-over-year to $2.8 million; the trailing twelve-month figure through Jun 2026 stood at $3.7 million (up 19.41% YoY), and the FY2025 full-year result was $2.2 million, down 39.46% from the prior year.
• Revenue grew to $2.8 million in Q1 2026 per ALGS's latest filing, from $169000.0 in the prior quarter.
• Across five years, Revenue topped out at $4.3 million in Q2 2023 and bottomed at $169000.0 in Q4 2025.
• Historically, Revenue has averaged $2.0 million across 5 years, with a median of $2.0 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Revenue surged 863.76% in 2022, then plunged 75.29% in 2024.
• Over 5 years, Revenue stood at $3.5 million in 2022, then sank by 43.2% to $2.0 million in 2023, then slumped by 69.84% to $606000.0 in 2024, then tumbled by 72.11% to $169000.0 in 2025, then jumped by 1574.56% to $2.8 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $2.8 million, $169000.0, and $741000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.